Non-alcoholic fatty liver disease (NAFLD) is an increasingly recognized condition, often associated with obesity and type 2 diabetes. Understanding its pathogenesis, diagnosis, and treatment is crucial for managing this global health concern.
NAFLD is characterized by excessive hepatic fat accumulation not due to alcohol consumption. It is a multifactorial disease, with insulin resistance and metabolic syndrome playing pivotal roles. The 'two-hit' hypothesis suggests that the first 'hit' involves accumulation of triglycerides in the liver, followed by a second 'hit' of increased oxidative stress leading to inflammation and fibrosis.
NAFLD is often asymptomatic and discovered incidentally during imaging studies. Liver function tests may show elevated aminotransferases. Ultrasound, CT, and MRI can detect hepatic steatosis, but liver biopsy remains the gold standard for diagnosing NAFLD and differentiating it from non-alcoholic steatohepatitis (NASH).
Management of NAFLD primarily focuses on lifestyle modifications including weight loss and increased physical activity. Pharmacological interventions are considered for patients with NASH or fibrosis. These include vitamin E, pioglitazone, and more recently, drugs targeting specific pathways involved in NAFLD pathogenesis, such as obeticholic acid and elafibranor. Liver transplantation is considered for end-stage liver disease.
NAFLD is a complex disease with a multifaceted pathogenesis. Its diagnosis often requires a high degree of clinical suspicion and appropriate use of diagnostic modalities. Advanced treatment approaches are being developed, targeting the specific mechanisms involved in the disease process. As our understanding of NAFLD continues to evolve, so too will our approach to its management, promising better outcomes for patients afflicted with this condition.
1.
ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death
2.
Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.
3.
AI catches one-third of interval breast cancers missed at screening
4.
Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results
5.
Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says
1.
Lymphomatoid Papulosis: What You Need to Know
2.
Exploring the Potential of Cytologic Atypia in Cancer Diagnosis
3.
The Rise of Immunotherapy: New Advances in Cancer Treatment
4.
Exploring the Mysteries of Myxoma: A New Frontier in Medical Research
5.
Patient Management Following Organ-Preserving Cancer Interventions
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
3.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
4.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation